All In Biotech

NDA 203479 · Douglas Pharms

Versacloz

Clozapine · Oral · Atypical Antipsychotic

Last checked: Nov 20, 2026Latest source record: Jun 13, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2013

Feb 6, 2013

Approved uses

n/a

Original approval plus efficacy supplements

Registered trials

127

19 Phase 3, 11 recruiting

FAERS reports

0

71,543 serious, 11,485 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: SEVERE NEUTROPENIA; ORTHOSTATIC HYPOTENSION, BRADYCARDIA, AND SYNCOPE; SEIZURE; MYOCARDITIS, PERICARDITIS, AND CARDIOMYOPATHY; INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS WARNING: SEVERE NEUTROPENIA; ORTHOSTATIC HYPOTENSION, BRADYCARDIA, AND SYNCOPE; SEIZURE; MYOCARDITIS, PERICARDITIS, AND CARDIOMYOPATHY; INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS Severe Neutropenia VERSACLOZ has caused severe neutropenia which is associated with an increased risk of serious and potentially fatal infections. Prior to initiating VERSACLOZ treatment, obtain baseline ANC(s). VERSACLOZ initiation is not recommended in patients with a baseline ANC less than 1500/µL (less than 1000/µL for those with Benign Ethnic Neutropenia (also known as Duffy-null associated neutrophil count)). See recommendations for dosage modifications based on ANC levels...

What it is approved for

From the label in effect Sep 6, 2026.

VERSACLOZ is an atypical antipsychotic indicated for: Treatment of severely ill patients with schizophrenia who fail to respond adequately to standard antipsychotic treatment. Because of the risks of severe neutropenia and of seizure associated with its use, VERSACLOZ should be used only in patients who have failed to respond adequately to standard antipsychotic treatment (1.1). Reducing the risk of recurrent suicidal behavior in patients with schizophrenia or schizoaffective disorder who are judged to be at chronic risk for re-experiencing suicidal behavior (1.2). 1.1 Treatment-Resistant Schizophrenia VERSACLOZ is indicated for the treatment of severely ill patients with schizophrenia who fail to respond adequately to standard antipsychotic treatment. Because of the risks of severe neutropenia and of seizure associated with its use, VERSACLOZ should be used only in patients who have failed to respond adequately to standard antipsychotic treatment [see Warnings and Precautions (5.1 , 5.4) ] . The effectiveness of clozapine in treatment-resistant schizophrenia was demonstrated in a 6-week, randomized, double-blind, active-controlled study comparing clozapine and chlorpromazine in patients who had failed other antipsychotics [see Clinical Studies (14.1) ] . 1.2 Reduction in the Risk of Recurrent Suicidal Behavior in Schizophrenia or Schizoaffective Disorders VERSACLOZ is indicated for reducing the risk of recurrent suicidal behavior in patients with schizophrenia or schizoaffective disorder who are judged to be at chronic risk for re-experiencing suicidal behavior, based on history and recent clinical state. Suicidal behavior refers to actions by a patient that put him/herself at risk for death. The effectiveness of clozapine in reducing the risk of recurrent suicidal...

Mechanism: The mechanism of action of clozapine is unknown. However, it has been proposed that the therapeutic efficacy of clozapine in schizophrenia is mediated through antagonism of the dopamine type 2 (D 2 ) and the serotonin type 2A (5-HT 2A ) receptors. VERSACLOZ also acts as an antagonist at adrenergic, cholinergic, histaminergic and other dopaminergic and serotonergic receptors.

Therapeutic areas: Psychiatry

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

FDA's data service returned an error (500). The numbers below may be missing or incomplete.

No approvals could be loaded from Drugs@FDA just now.

Clinical trials

Interventional ClinicalTrials.gov studies with "Clozapine" as an intervention, any sponsor and status, largest first.

All 127 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
FDA's data service returned an error (500). The numbers below may be missing or incomplete.
  • neutropenia16,561
  • hospitalisation7,715
  • death5,563
  • drug ineffective3,193
  • drug interaction2,832
  • granulocytopenia2,567
  • off label use2,157
  • psychotic disorder1,915
  • leukopenia1,747
  • neutrophilia1,694
  • agranulocytosis1,651
  • toxicity to various agents1,639

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20041,168
2005931
20062,035
2007477
2008441
2009531
20101,063
20113,917
20121,657
2013858
2014926
20151,307
20163,401
20174,411
20183,864
20194,510
20204,796
20214,528
202210,809
20239,614
20248,031
20255,048
20262,793

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Versacloz (Clozapine)

2024 spending

$1.3M

Beneficiaries

97

928 claims

Per beneficiary

$13,906

$8.77 per unit

View as table
YearSpending
2020$797,711
2021$1,014,050
2022$1,200,112
2023$1,268,676
2024$1,348,878

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 1,392 on PubMed

Sponsor: Douglas Pharms

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.